Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion.
Saved in:
| Title: | Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion. |
|---|---|
| Authors: | Lee TH; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea., Lee H; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Jang JY; Department of Radiation Oncology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea., Park W; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea., Cho WK; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea., Cho EY; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Park YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Nam SJ; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Kim SW; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Lee JE; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Kim H; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. haeyoung0131.kim@samsung.com. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2026 Feb 05; Vol. 215 (3), pp. 76. Date of Electronic Publication: 2026 Feb 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41642482 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Lee+TH%22">Lee TH</searchLink>; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+H%22">Lee H</searchLink>; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Jang+JY%22">Jang JY</searchLink>; Department of Radiation Oncology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Park+W%22">Park W</searchLink>; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cho+WK%22">Cho WK</searchLink>; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cho+EY%22">Cho EY</searchLink>; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ahn+JS%22">Ahn JS</searchLink>; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Park+YH%22">Park YH</searchLink>; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Nam+SJ%22">Nam SJ</searchLink>; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+SW%22">Kim SW</searchLink>; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+JE%22">Lee JE</searchLink>; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+H%22">Kim H</searchLink>; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. haeyoung0131.kim@samsung.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2026 Feb 05; Vol. 215 (3), pp. 76. <i>Date of Electronic Publication: </i>2026 Feb 05. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41642482 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10549-026-07906-8 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 76 Titles: – TitleFull: Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lee TH – PersonEntity: Name: NameFull: Lee H – PersonEntity: Name: NameFull: Jang JY – PersonEntity: Name: NameFull: Park W – PersonEntity: Name: NameFull: Cho WK – PersonEntity: Name: NameFull: Cho EY – PersonEntity: Name: NameFull: Ahn JS – PersonEntity: Name: NameFull: Park YH – PersonEntity: Name: NameFull: Nam SJ – PersonEntity: Name: NameFull: Kim SW – PersonEntity: Name: NameFull: Lee JE – PersonEntity: Name: NameFull: Kim H IsPartOfRelationships: – BibEntity: Dates: – D: 05 M: 02 Text: 2026 Feb 05 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1573-7217 Numbering: – Type: volume Value: 215 – Type: issue Value: 3 Titles: – TitleFull: Breast cancer research and treatment Type: main |
| ResultId | 1 |
